Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

Decisions 27th November 2018

Checked: not set yet by Next Review: not set yet

At the meeting on the 27th November the following decisions were agreed:

 

New Drug Requests

 

Approved

Melatonin (amber 3 months)

  • Approved for adults with Learning Disabilities with co-morbid mental illness or with sleep disturbances pending an amended SCP

Cacicol® 

  • Approved for the management of corneal wound healing on the eye

 

Further work needed

Glycopyrronium 

  • The group agreed that further work was needed before it could be added onto the Formulary for drooling in Parkinson's disease patient's

Botulinum toxin

  • The group agreed that further work was needed before it could be added onto the Formulary for drooling in Parkinson's disease and Motor Neurone Disease

Melatonin 

  • The group felt there were questions that needed answering before a decision could be made for the use of melatonin for REM Sleep Behaviour Disorder.  Unfortunately the applicant was unable to attend.  The application will be discussed in April.

 

Not approved

Melatonin

  • Not approved for Delayed Sleep-Wake Phase Disorder

Adex gel

  • Not approved for vascular eczema and psoriasis

 

Shared Care Protocols/TLS Status

  •  Appeal for change of TLS from amber to green for Dymista® approved.